Assessment of HER-2/Neu status by immunohistochemistry and fluorescence in situ hybridization in mammary paget disease and underlying carcinoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 11, Issue 2, 2003, Pages 120-124

  Anderson, Joseph M ^a   Ariga, Reshma ^a   Govil, Hema ^a   Bloom, Kenneth J ^a   Francescatti, Darius ^a   Reddy, Vijaya B ^a   Gould, Victor E ^a   Gattuso, Paolo ^a,b  

^a RUSH MEDICAL COLLEGE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Breast cancer; FISH; HER 2 Neu; Immunohistochemistry; Paget

Indexed keywords

ESTROGEN RECEPTOR; FORMALDEHYDE; PARAFFIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; ONCOGENE NEU; PAGET NIPPLE DISEASE; PRIORITY JOURNAL; TISSUE FIXATION; TUMOR CELL;

EID: 0037899012     PISSN: 15412016     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129039-200306000-00005     Document Type: Article

References (31)

1. Lloyd J, Flanagan AM. Mammary and extramammary Paget's disease. J Clin Pathol. 2000;53:742-9.
2. Jones RR, Spaull J, Gusterson B. The histogenesis of mammary and extramammary Paget's disease. Histopathology. 1989;14:409-16.
3. Sakorafas GH, Blanchard DK, Sarr MG, et al. Paget's disease of the breast: a clinical perspective. Langenbecks Arch Surg. 2001;386:444-50.
4. Fu W, Mittel VK, Young SC. Paget disease of the breast: analysis of 41 patients. Am J Clin Oncol. 2001;24:397-400.
5. Fourquet A, Campana F, Vielh P, et al. Paget's disease of the nipple without detectable breast tumor: conservative management with radiation therapy. Int J Radiat Oncol Biol Phys. 1987;13:1463-5.
6. Keatings L, Sinclair J, Wright C, et al. C-erbB-2 oncoprotein expression in mammary and extramammary Paget's disease: an immunohistochemical study. Histopathology. 1990;17:243-7.
7. Wolber RA, Dupuis BA, Wick MR. Expression of c-erbB-2 oncoprotein in mammary and extramammary Paget's disease. Am J Clin Pathol. 1991;2:243-7.
8. Meissner K, Riviere A, Haupt G, et al. Study of neu-protein expression in mammary Paget's disease with and without underlying breast carcinoma and in extramammary Paget's disease. Am J Pathol. 1990;137:1305-9.
9. Mai KT, Yazdi HM, Perkins DG. Mammary Paget's disease: evidence of diverse origin of the disease with a subgroup of Paget's disease developing from the superficial portion of lactiferous duct and a discontinuous pattern of tumor spread. Pathol Int. 1999;49:956-61.
10. Lundquist K, Kohler S, Rouse RV. Intraepidermal cytokeratin 7 expression is not restricted to Paget cells but is also seen in Toker cells and Merkel cells. Am J Surg Pathol. 1999;23:212-9.
11. Smith KJ, Tuur S, Corvette D, et al. Cytokeratin 7 staining in mammary and extramammary Paget's disease. Mod Pathol. 1997;10:1069-74.
12. Yao DX, Hoda SA, Chiu A, et al. Intraepidermal cytokeratin 7 immunoreactive cells in the non-neoplastic nipple may represent interepithelial extension of lactiferous duct cells. Histopathology. 2002;40:230-6.
13. Mai KT. Morphological evidence for field effect as a mechanism for tumor spread in mammary Paget's disease. Histopathology. 1999:35:567-76.
14. Schelfhout VR, Coene ED, Delaey B, et al. Pathogenesis of Paget's disease: epidermal heregulin-alpha, motility factor, and the HER receptor family. J Natl Cancer Inst. 2000;92:622-8.
15. Fu W, Lobocki CA, Silberberg BK, et al. Molecular markers in Paget's disease of the breast. J Surg Oncol Suppl. 2001;77:171-8.
16. Lupu R, Cardillo M, Harris L, et al. Interaction between ERB receptors and heregulin in breast cancer tumor progression and drug resistance. Semin Cancer Biol. 1995;6:135-45.
17. Slamon DJ, Clark GM. Amplification of C-erb2 and aggressive breast tumors? Science. 1988;240:1795-8.
18. Depotter CR. The neu oncogene: more than a prognostic indicator? Hum Pathol. 1994;25:1264-8.
19. Xu R, Perle MA, Inghirami G, et al. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol. 2002;15:116-24.
20. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the Her2/Neu protooncogene in human breast and ovarian cancer. Science. 1989;244:707-12.
21. Allred DC, Clark GM, Molina R, et al. Immunocytochemical analysis of Her2/Neu oncogene expression in in-situ and invasive breast carcinomas: evaluation of pathological characteristics and biological significance. Lab Invest. 1990;62:3A.
22. Van de Vijver MJ, Petersen JL, Mooi WJ, et al. Neu protein over expression in breast cancer: association with comedo type ductal carcinoma in-situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988;319:1239-45.
23. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol. 1999;112(suppl 1):S53-67.
24. Moriki T, Takahashi T, Hoiroi M, et al. Histological grade in invasive ductal carcinoma of the breast correlates with the proliferative activity evaluated by BrdU: an immunohistochemical study including correlations with p53, c-erB-2 and estrogen receptor status. Pathol Int. 1996;46:417-25.
25. Joonjic N, Mustac E, Krstulja M, et al. Nuclear grade in invasive ductal breast carcinoma: comparative study on nuclear grade and morphometric parameters, hormonal receptor status, flow cytometric analysis and lectin histochemistry. Gen Diagn Pathol, 1996;142:83-8.
26. Ruibal A, Arias JI, Del Rio MC, et al. The correlations of clinicopathologic features, hormone receptor level with the prognosis of breast cancer: report of 308 cases in elderly women. Clin Med Sci J. 1997;12:60-2.
27. Shi Y, He L, Chen Y, et al. Histological grade in breast cancer: association with clinical and biological features in a series of 229 patients. Int J Biol Markers. 2001;16:56-61.
28. Pinto AE, Andre S, Nobrega S, et al. C-erB-2 oncoprotein over-expression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis. Ann Oncol. 2001;12:525-33.
29. Ferrero-Pous M, Hacene K, Bouchet C, et al. Relationship between C-erb-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res. 2000;6:4745-54.
30. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 1998;16:413-28.
31. Cobleigh MA, Vogel CL, Tripathy NJ, et al. Efficacy and safety of Herceptin as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer [abstract]. Proceedings of the American Society of Clinical Oncology, vol. 17. Alexandria. VA: American Society of Clinical Oncology, 1998:97.